Cargando…
Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report
BACKGROUND: Human epidermal receptor-2 (HER-2) expression has been reported to be discordant between primary tumor and metastatic tissue. CASE SUMMARY: We presented a case diagnosed with the HER-2+ breast cancer patient who exhibited changes in the expression of HER-2 receptors on tumour samples fro...
Autores principales: | Yu, Jing, Li, Nan-Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258374/ https://www.ncbi.nlm.nih.gov/pubmed/35979138 http://dx.doi.org/10.12998/wjcc.v10.i17.5923 |
Ejemplares similares
-
Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer
por: Cho, Dong Hui, et al.
Publicado: (2013) -
Human Epidermal Growth Factor Receptor 2-Subtype Invasive Ductal Carcinoma Recurring as Basal-Human Epidermal Growth Factor Receptor 2-Subtype Squamous Cell Carcinoma
por: An, Jeongshin, et al.
Publicado: (2019) -
Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
por: Huober, Jens, et al.
Publicado: (2022) -
Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer
por: Alves, Fátima R, et al.
Publicado: (2022) -
Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials
por: Nahleh, Zeina, et al.
Publicado: (2019)